Posted by Michael Wonder on 21 Oct 2022
Revance submits supplemental biologics license application for Daxxify (daxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia
20 October 2022 - Supplemental biologics license application filing based on the pivotal ASPEN Phase 3 program demonstrating Daxxify's median duration of response of 24 weeks in the treatment of cervical dystonia.
Revance Therapeutics today announced that it has submitted a supplemental biologics license application to the US FDA for Daxxify for the treatment of cervical dystonia.
